By expanding its immunology product portfolio of EliA autoimmune diagnostics, ImmunoCAP™ allergy diagnostics, and Phadia Laboratory Systems with complimentary reagents and systems from Aesku, Thermo Fisher Scientific will continue to meet the evolving needs of laboratories and healthcare professionals, enabling faster and more accurate diagnoses for patients.

OCSiAl’s exceptional graphene nanotubes -based solution addresses these issues, ushering in a new era of silicone PSA technology. The user-friendly nanotube dispersion TUBALLTM MATRIX 617 results in excellent electrical conductivity combined with more than 90% transparency in a wide range of peeling-strength PSA films.

“Our latest study is the result of six years of focused research, delivering a practical model that allows users to predict metabolic pathways for a wide range of drug-like compounds. Thanks to our carefully curated datasets and our signature reactivity-accessibility approach, we have managed to build accurate isoform-specific regioselectivity models for the important Phase I and II enzyme families” Dr Mario Öeren, Principal Scientist, Optibrium said

The Nevisense System is a first-of-its-kind AI-driven technology that uniquely addresses the complexities of point-of-care detection of the deadliest form of skin cancer by providing clinicians with advanced analysis of irregular moles during routine skin checks.

“We are pleased to enter into this collaboration with Lycia Therapeutics, extending our service footprint to the area of extracellular protein degradation. We believe Lycia’s leveraging of our antibody discovery capabilities will help accelerate its efforts to advance novel protein degrader therapeutics,” said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences said.